Skip to content

Pharmaceuticals in Brazil Final Customers Identification

Customers Categorization

Based on the value chain analysis of the pharmaceutical industry in Brazil, the final customers, where products reach their ultimate point of consumption or dispensing to the end-user, can be categorized into Business-to-Business (B2B), Business-to-Consumer (B2C), and notably, Business-to-Government (B2G) segments. While the request specifically asks for B2B and B2C, the B2G segment (the Public Health System - SUS) is a critical final destination for pharmaceutical products in Brazil and is supplied through B2B-like transactions (tenders, direct purchases).

Here's the categorization of final customers within the context of the value chain:

  • B2C Customers:

    • Individual Consumers/Patients: These are the ultimate recipients of pharmaceutical products. They purchase medicines and other health-related items directly from retail pharmacies. This interaction represents the direct B2C transaction at the very end of the chain. The growing retail market, which moved R$ 158.4 billion in 2024 with 8.1 billion units sold, highlights the significant volume of B2C transactions.

  • B2B Customers:

    • Retail Pharmacies (Chains, Associative Networks, and Independents): Although they are the point of sale to the B2C customer, retail pharmacies themselves are customers of the preceding stages (Distribution and sometimes Pharmaceutical Production). They purchase finished pharmaceutical products in bulk from wholesale distributors or directly from manufacturers (B2B transactions) for subsequent sale to consumers. Brazil had approximately 93,700 pharmacies and drugstores in activity in 2024. The large pharmacy chains like RD Saúde, Grupo DPSP, and Grupo Pague Menos are significant B2B customers due to their purchasing volumes and market share concentration.
    • Hospitals and Clinics: These institutions purchase pharmaceutical products, medical supplies, and specialized medicines from manufacturers or specialized hospital distributors (B2B transactions) to administer to patients within their facilities. Hospital pharmacies manage this supply within the healthcare institution.

  • B2G Customers (Significant Final Customer Type):

    • Public Health System (Sistema Único de Saúde - SUS): The Brazilian government, through the SUS, is a major purchaser of pharmaceutical products from manufacturers and distributors. These are B2G transactions conducted primarily through public tenders and procurement processes to supply medicines, often essential or high-cost, to public hospitals, health posts, and programs for free or subsidized distribution to the population. While the end recipient is the patient (C), the direct customer in this part of the value chain flow is the government entity.

Detailed Profiles of Customer Characteristics and Demographics

Based on the provided text, here are characteristics and demographics of the identified final customer segments:

  • Individual Consumers/Patients (B2C):

    • Characteristics: Motivated by health needs, seeking access to a wide range of medicines (prescription and over-the-counter), and increasingly interested in convenience and additional health services offered at pharmacies (like vaccinations and basic health checks). Their purchasing power and healthcare access are noted as drivers for market growth.
    • Demographics: The market growth is partly attributed to an aging population, indicating a significant segment of elderly patients requiring medication. The increasing access to healthcare suggests a broader demographic reach across different income levels. Demand is high, with the retail market selling billions of units annually. Consumer preference strongly favors increased domestic production of medicines and inputs, with 90% of Brazilians expressing this preference.

  • Retail Pharmacies (B2B):

    • Characteristics: Operate in a highly competitive environment, particularly among the large chains. They function as the primary interface with the end consumer. Large chains are characterized by extensive national presence, high store productivity, wide product offerings (including non-medicinal items), and investment in customer experience and integrated health services ("health hub" model). Independent pharmacies often focus on personalized service and community ties. The segment is undergoing significant consolidation, with the top three groups concentrating a large portion of the consumer market share. They manage inventory, sales, marketing, and regulatory compliance at the point of sale.
    • Demographics (of their customer base): Serve the general population across all demographics who require access to pharmaceutical products and related goods and services. The rise of "health hubs" indicates a strategic targeting of consumers seeking convenient health and wellness services locally.

  • Hospitals and Clinics (B2B):

    • Characteristics: Require a consistent and reliable supply of a broad spectrum of pharmaceutical products, including specialized and high-cost medications for inpatient and outpatient treatment. They necessitate specific types of distribution (hospital distribution) that can handle specialized storage and delivery requirements. Their procurement processes are driven by patient needs and institutional formularies.

  • Public Health System (SUS) (B2G):

    • Characteristics: Acts as a massive institutional buyer with the objective of ensuring broad access to essential and strategic medicines for the Brazilian population, often free of charge or at subsidized costs. Procurement is carried out through formal tender processes, subject to government regulations and budgetary constraints. This segment represents a significant volume of the pharmaceutical market, particularly for vaccines and treatments for prevalent diseases. There is a strong public expectation for the SUS to provide necessary medications.

References:

  • Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas.
  • Abradilan. Dez maiores farmacêuticas detêm 48,6% das vendas.
  • Abradilan. Crescimento das grandes redes de farmácias.
  • Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor.
  • Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos.
  • Anvisa. Anvisa divulga dados do anuário sobre a indústria farmacêutica no Brasil.
  • Anvisa. Aprovado novo marco regulatório de BPF.
  • BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas.
  • CDPI Pharma. O tamanho da indústria farmacêutica nacional.
  • CDPI Pharma. O investimento da indústria farmacêutica em pesquisa e desenvolvimento.
  • CFF Admin. Por que o Brasil não avança na pesquisa e desenvolvimento de ativos farmacêuticos?.
  • CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos.
  • Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025).
  • Faz Acontecer. Investimento em P&D pela indústria farmacêutica bate recorde em 2022.
  • Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025.
  • FIA. Indústria farmacêutica: características, setores e mercado de trabalho.
  • Grupo FarmaBrasil. Pesquisa, desenvolvimento e inovação no Setor Farmacêutico: o Brasil no cenário internacional.
  • Grupo Palmed. Distribuidoras de Medicamentos.
  • ICTQ. 14 atualizações regulatórias para a Indústria Farmacêutica em 2018.
  • ICTQ. Os modelos de negócios farmacêuticos.
  • ICTQ. Anvisa - Confira as principais atualizações regulatórias que ocorreram nos últimos seis meses.
  • InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento.
  • MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama.
  • MOOC Fiocruz. Estágios da produção de medicamentos.
  • Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país.
  • Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil.
  • Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil.
  • Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024.
  • Natcofarma. Varejo farmacêutico: Confira as principais tendências.
  • Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?.
  • Panorama Farmacêutico. Dez maiores laboratórios do Brasil têm 55% do mercado.
  • Quais são as maiores empresas farmacêuticas do Brasil e do mundo?.
  • Qualifica. Legislação Sanitária para Indústria Farmacêutica: o que mudou?.
  • Sebrae. Como montar uma distribuidora de medicamentos.
  • Sotequi Vedações Industriais. Segmento farmaceutica.
  • Sulmedic. Distribuição de Medicamentos Hospitalares.
  • Os Tipos de Empresas Farmacêuticas :: Gestão Farmacêutica.
  • VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar.
  • VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024.
  • Vernalha Pereira. Novas regras da Anvisa e o seu impacto no registro de medicamentos para a indústria farmacêutica.